Literature DB >> 15068504

Longitudinal in vivo effects of growth hormone overexpression on bone in transgenic mice.

Felix Eckstein1, Axel Weusten, Corina Schmidt, Ulrich Wehr, Rüdiger Wanke, Walter Rambeck, Eckhard Wolf, Subburaman Mohan.   

Abstract

UNLABELLED: In this study we examined the effect of systemic overexpression of GH on bone in transgenic mice longitudinally in vivo over a period of 9 months. We observed substantially increased BMC in GH transgenic mice and a significant reduction in serum osteocalcin. GH effects on bone were strongly dependent on gender and developmental stage.
INTRODUCTION: State-of-the-art bone marker and microimaging technology was applied in this longitudinal study to examine bone metabolism, BMC, bone density, and cortical bone structure over the life span of growth hormone (GH) transgenic (tg) mice.
MATERIALS AND METHODS: Thirty-eight mice from four genetic groups (male, female, tg, and controls) were examined with DXA, and their femur and tibia were examined with peripheral QCT (pQCT). Osteocalcin (formation) and collagen cross-links (resorption) from serum and urine were also measured at postnatal weeks 3, 6, 9, 12, 18, 26, and 38.
RESULTS: GH tg mice displayed a significant increase in body weight (up to 50%) and BMC (up to 90%), but serum osteocalcin was significantly reduced compared with controls. GH tg females (but not males) displayed increased trabecular density over controls up to week 12. In contrast, male (but not female) GH tg mice displayed a higher cortical cross-sectional area than controls. Cortical density was significantly lower in both male and female GH tg mice compared with control mice.
CONCLUSIONS: The increase in BMC in GH tg mice is associated with reduced serum osteocalcin levels, indicating that bone turnover may be lower than in the control mice. On a structural level, bone responds to GH excess in a gender-specific manner, with alterations varying substantially between different developmental stages.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15068504     DOI: 10.1359/JBMR.040308

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  8 in total

Review 1.  Regulation of skeletal growth and mineral acquisition by the GH/IGF-1 axis: Lessons from mouse models.

Authors:  Shoshana Yakar; Olle Isaksson
Journal:  Growth Horm IGF Res       Date:  2015-09-28       Impact factor: 2.372

2.  Impaired skeletal growth in mice with haploinsufficiency of IGF-I: genetic evidence that differences in IGF-I expression could contribute to peak bone mineral density differences.

Authors:  S Mohan; D J Baylink
Journal:  J Endocrinol       Date:  2005-06       Impact factor: 4.286

Review 3.  Musculoskeletal Effects of Altered GH Action.

Authors:  Jonathan A Young; Shouan Zhu; Edward O List; Silvana Duran-Ortiz; Yosri Slama; Darlene E Berryman
Journal:  Front Physiol       Date:  2022-05-19       Impact factor: 4.755

4.  Excessive growth hormone expression in male GH transgenic mice adversely alters bone architecture and mechanical strength.

Authors:  S V Lim; M Marenzana; M Hopkinson; E O List; J J Kopchick; M Pereira; B Javaheri; J P Roux; P Chavassieux; M Korbonits; C Chenu
Journal:  Endocrinology       Date:  2015-02-03       Impact factor: 4.736

Review 5.  Effects of GH/IGF axis on bone and cartilage.

Authors:  Manisha Dixit; Sher Bahadur Poudel; Shoshana Yakar
Journal:  Mol Cell Endocrinol       Date:  2020-10-14       Impact factor: 4.102

6.  Combined growth hormone and insulin-like growth factor-1 rescues growth retardation in glucocorticoid-treated mdxmice but does not prevent osteopenia.

Authors:  Claire L Wood; Rob van 't Hof; Scott Dillon; Volker Straub; Sze C Wong; S Faisal Ahmed; Colin Farquharson
Journal:  J Endocrinol       Date:  2022-03-29       Impact factor: 4.669

7.  Direct stimulation of bone mass by increased GH signalling in the osteoblasts of Socs2-/- mice.

Authors:  R Dobie; V E MacRae; C Huesa; R van't Hof; S F Ahmed; C Farquharson
Journal:  J Endocrinol       Date:  2014-07-29       Impact factor: 4.286

8.  Suppressor of cytokine signaling 2 (Socs2) deletion protects bone health of mice with DSS-induced inflammatory bowel disease.

Authors:  Ross Dobie; Vicky E MacRae; Chloe Pass; Elspeth M Milne; S Faisal Ahmed; Colin Farquharson
Journal:  Dis Model Mech       Date:  2018-01-17       Impact factor: 5.758

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.